Kelley Drye: Health Care Policy Reform Agenda Puts Reverse Payment Agreements Between Branded and Generic Drug Makers in the Spotlight: Proposals to Ban Payments Gaining Momentum | Practical Law

Kelley Drye: Health Care Policy Reform Agenda Puts Reverse Payment Agreements Between Branded and Generic Drug Makers in the Spotlight: Proposals to Ban Payments Gaining Momentum | Practical Law

This Kelley, Drye & Warren LLP memorandum discusses recent and upcoming developments regarding reverse payment pharmaceutical settlements including: an unresolved circuit split, harmonizing the Department of Justice (DOJ) and Federal Trade Commission (FTC) antitrust approaches and much litigation.

Kelley Drye: Health Care Policy Reform Agenda Puts Reverse Payment Agreements Between Branded and Generic Drug Makers in the Spotlight: Proposals to Ban Payments Gaining Momentum

by Kelley, Drye & Warren LLP
Published on 12 Aug 2010 • USA (National/Federal)
This Kelley, Drye & Warren LLP memorandum discusses recent and upcoming developments regarding reverse payment pharmaceutical settlements including: an unresolved circuit split, harmonizing the Department of Justice (DOJ) and Federal Trade Commission (FTC) antitrust approaches and much litigation.